SYDNEY, Jan. 23, 2018 /PRNewswire/ -- Benitec
Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) advises
that it has received a $4,112,058
cash refund for the year ended 2017 under the Federal Government's
R&D Tax Incentive Scheme.
The refund relates to the costs of research and development
which qualify as eligible R&D expenditure under the Federal
Government's Scheme. The funds will be used to advance
Benitec's human therapeutic programs in gene silencing.
For further information regarding Benitec please contact the
persons below or visit the Benitec website at www.benitec.com.
Australia
Investor Relations
|
United States
Investor Relations
|
|
|
Market Eye
Orla
Keegan
Director
Tel: +61 (2) 8097
1201
Email:
orla.keegan@marketeye.com.au
|
M Group Strategic
Communications
Jay
Morakis
Managing
Director
Tel: +1
212.266.0190
Email:
jmorakis@MGroupSC.com
|
About Benitec Biopharma Limited:
Benitec
Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a
biotechnology company developing innovative therapeutics based on
its patented gene-silencing technology called ddRNAi or 'expressed
RNAi'. Based in Sydney, Australia
with laboratories in Hayward,
California (USA), and collaborators and licensees around the
world, the company is developing ddRNAi-based therapeutics for
chronic and life-threatening human conditions including hepatitis
B, wet age-related macular degeneration and OPMD. Benitec has also
licensed ddRNAi to other biopharmaceutical companies for
applications including HIV/AIDS, Huntington's Disease, chronic
neuropathic pain and retinitis pigmentosa.
Safe Harbor Statement:
This press
release contains "forward-looking statements" within the meaning of
section 27A of the US Securities Act of 1933 and section 21E of the
US Securities Exchange Act of 1934. Any forward-looking statements
that may be in the press release are subject to risks and
uncertainties relating to the difficulties in Benitec's plans to
develop and commercialize its product candidates, the timing of the
initiation and completion of preclinical and clinical trials, the
timing of patient enrolment and dosing in clinical trials, the
timing of expected regulatory filings, the clinical utility and
potential attributes and benefits of ddRNAi and Benitec's product
candidates, potential future out-licenses and collaborations, the
intellectual property position and the ability to procure
additional sources of financing. Accordingly, you should not rely
on those forward-looking statements as a prediction of actual
future results.
View original
content:http://www.prnewswire.com/news-releases/federal-rd-tax-credit-received-300587013.html
SOURCE Benitec Biopharma Limited